Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 10/2023

11-03-2023 | Multiple Myeloma | Review

CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment

Authors: Shunshun Bao, Mohammad Darvishi, Ali H Amin, Maysoon T. Al-Haideri, Indrajit Patra, Khadisha Kashikova, Irfan Ahmad, Fahad Alsaikhan, Zahraa Haleem Al-qaim, Moaed E. Al-Gazally, Bahman Abedi Kiasari, Bahareh Tavakoli-Far, Akmal A. Sidikov, Yasser Fakri Mustafa, Reza Akhavan-Sigari

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2023

Login to get access

Abstract

CXC chemokine receptor type 4 (CXCR4) is a member of the G protein-coupled receptors (GPCRs) superfamily and is specific for CXC chemokine ligand 12 (CXCL12, also known as SDF-1), which makes CXCL12/CXCR4 axis. CXCR4 interacts with its ligand, triggering downstream signaling pathways that influence cell proliferation chemotaxis, migration, and gene expression. The interaction also regulates physiological processes, including hematopoiesis, organogenesis, and tissue repair. Multiple evidence revealed that CXCL12/CXCR4 axis is implicated in several pathways involved in carcinogenesis and plays a key role in tumor growth, survival, angiogenesis, metastasis, and therapeutic resistance. Several CXCR4-targeting compounds have been discovered and used for preclinical and clinical cancer therapy, most of which have shown promising anti-tumor activity. In this review, we summarized the physiological signaling of the CXCL12/CXCR4 axis and described the role of this axis in tumor progression, and focused on the potential therapeutic options and strategies to block CXCR4.
Literature
Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, Nagler A, Peled A (2007) Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 25(9):2158–2166PubMed
Abraham M, Klein S, Bulvik B, Wald H, Weiss ID, Olam D, Weiss L, Beider K, Eizenberg O, Wald O, Galun E, Avigdor A, Benjamini O, Nagler A, Pereg Y, Tavor S, Peled A (2017) The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression. Leukemia 31(11):2336–2346PubMed
Afshar-Khamseh R, Javeri A, Taha MF (2021) MiR-146a suppresses the expression of CXCR4 and alters survival, proliferation and migration rate in colorectal cancer cells. Tissue Cell 73:101654PubMed
Akashi T, Koizumi K, Tsuneyama K, Saiki I, Takano Y, Fuse H (2008) Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer. Cancer Sci 99(3):539–542PubMed
Alghasi A, Farnoosh G, Boroujeni AS, Bahadoram M, Gandomkari ST, Mahmoudian-Sani M-R (2021) Single nucleotide polymorphisms associated with gastric cancer in Iranian patients. Immunopathol Persa 7(2):6
Aliyari-Serej Z, Ebrahimi A, Kazemi T, Najafi S, Roshani E, Ebrahimi-Kalan M, Baradaran B (2020) Relation between Immune cell response and stemness genes expression in breast cancer; a new approach in NANOG gene and Let7-a expression in breast cancer cell lines. Immunopathol Persa 6(2):e21–e21
Ameen F, Al-Maary KS, Almansob A, AlNadhari S (2022) Antioxidant, antibacterial and anticancer efficacy of Alternaria chlamydospora-mediated gold nanoparticles. Appl Nanosci 1–8
Amri A, Soltanian AR, Borzouei S (2022) Survival rates and prognostic factors of thyroid cancer: a retrospective cohort study. J Parathyr Dis 10:e11162
Andritsos LA, Byrd JC, Cheverton P, Wu J, Sivina M, Kipps TJ, Burger JA (2019) A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leuk Lymphoma 60(14):3461–3469PubMed
Andtbacka R, Pierce RH, Campbell JS, Yushak M, Milhem M, Ross MI, Grossmann KF, Sprott K, Tsiroyannis E, Niland K (2018) X4P–001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma. Cancer Res 400:200
Aravindan S, Ramraj S, Kandasamy K, Thirugnanasambandan SS, Somasundaram DB, Herman TS, Aravindan N (2017) Hormophysa triquerta polyphenol, an elixir that deters CXCR4-and COX2-dependent dissemination destiny of treatment-resistant pancreatic cancer cells. Oncotarget 8(4):5717PubMed
Ardalan M (2016) Parathyroid carcinoma; an updated mini-review on current trends. J Parathyr Dis 4(2):57–59
Bachelder RE, Wendt MA, Mercurio AM (2002) Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 62(24):7203–7206PubMed
Balkwill F (2004a) Cancer and the chemokine network. Nat Rev Cancer 4(7):540–550PubMed
Balkwill F (2004b) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14(3):171–179PubMed
Baral S, Pariyar R, Kim J, Lee HS, Seo J (2017) Quercetin-3-O-glucuronide promotes the proliferation and migration of neural stem cells. Neurobiol Aging 52:39–52PubMed
Barbero S, Bonavia R, Bajetto A, Porcile C, Pirani P, Ravetti JL, Zona GL, Spaziante R, Florio T, Schettini G (2003) Stromal cell-derived factor 1α stimulates human glioblastoma cell growth through the activation of both extracellular signal-regulated kinases 1/2 and Akt. Can Res 63(8):1969–1974
Barbieri F, Bajetto A, Thellung S, Wurth R, Florio T (2016) Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma. Expert Opin Drug Discov 11(11):1093–1109PubMed
Bartolomé RA, Ferreiro S, Miquilena-Colina ME, Martínez-Prats L, Soto-Montenegro ML, García-Bernal D, Vaquero JJ, Agami R, Delgado R, Desco M (2009) The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol 174(2):602–612PubMedPubMedCentral
Becker PS, Foran JM, Altman JK, Yacoub A, Castro JE, Sabbatini P, Dilea C, Wade M, Xing G, Gutierrez A (2014) Targeting the CXCR4 pathway: safety, tolerability and clinical activity of ulocuplumab (BMS-936564), an anti-CXCR4 antibody, in relapsed/refractory acute myeloid leukemia. Blood 124(21):386
Beider K, Begin M, Abraham M, Wald H, Weiss ID, Wald O, Pikarsky E, Zeira E, Eizenberg O, Galun E, Hardan I, Engelhard D, Nagler A, Peled A (2011) CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth. Exp Hematol 39(3):282–292PubMed
Beider K, Ribakovsky E, Abraham M, Wald H, Weiss L, Rosenberg E, Galun E, Avigdor A, Eizenberg O, Peled A, Nagler A (2013) Targeting the CD20 and CXCR4 pathways in non-Hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140. Clin Cancer Res 19(13):3495–3507PubMed
Beider K, Darash-Yahana M, Blaier O, Koren-Michowitz M, Abraham M, Wald H, Wald O, Galun E, Eizenberg O, Peled A, Nagler A (2014) Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo. Mol Cancer Ther 13(5):1155–1169PubMed
Berning P, Schaefer C, Clemens D, Korsching E, Dirksen U, Potratz J (2018) The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling. Cell Commun Signal 16(1):21PubMedPubMedCentral
Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI (2020) CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proc Natl Acad Sci USA 117(46):28960–28970PubMedPubMedCentral
Bobkov V, Zarca AM, Van Hout A, Arimont M, Doijen J, Bialkowska M, Toffoli E, Klarenbeek A, van der Woning B, van der Vliet HJ, Van Loy T, de Haard H, Schols D, Heukers R, Smit MJ (2018) Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions. Biochem Pharmacol 158:413–424PubMed
Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W, Bose P, Jabbour E, Estrov Z, Burger J, Alvarado Y, Deshmukh A, Patel A, Cavazos A, Han L, Cortes JE, Kantarjian H, Andreeff M, Konopleva M (2018) Initial report of a phase I study of LY2510924, idarubicin, and cytarabine in relapsed/refractory acute myeloid leukemia. Front Oncol 8:369PubMedPubMedCentral
Borthakur G, Tallman M, Ofran Y, Foran J, Uy G, DiPersio J, Nagler A, Rowe J, Showel M, Altman J (2018) The CXCR4 inhibitor BL-8040 in combination with cytarabine results in a significantly extended overall survival of relapsed/refractory AML patients. EHA Libr 215317:S993
Brave M, Farrell A, Ching Lin S, Ocheltree T, Pope Miksinski S, Lee SL, Saber H, Fourie J, Tornoe C, Booth B, Yuan W, He K, Justice R, Pazdur R (2010) FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 78(3–4):282–288PubMed
Broussas M, Boute N, Akla B, Berger S, Beau-Larvor C, Champion T, Robert A, Beck A, Haeuw J-F, Goetsch L (2016) A new anti-CXCR4 antibody that blocks the CXCR4/SDF-1 axis and mobilizes effector cells. Mol Cancer Ther 15(8):1890–1899PubMed
Burger JA, Burkle A (2007) The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 137(4):288–296PubMed
Burger JA, Peled A (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23(1):43–52PubMed
Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N, Kipps TJ, Burger JA (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106(5):1824–1830PubMed
Burger JA, Stewart DJ, Wald O, Peled A (2011) Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 11(4):621–630PubMed
Busillo JM, Benovic JL (2007) Regulation of CXCR4 signaling. Biochim Biophys Acta 1768(4):952–963PubMed
Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M, Benovic JL (2010) Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 285(10):7805–7817PubMedPubMedCentral
Cano-Garrido O, Alamo P, Sanchez-Garcia L, Falgas A, Sanchez-Chardi A, Serna N, Parlade E, Unzueta U, Roldan M, Volta-Duran E, Casanova I, Villaverde A, Mangues R, Vazquez E (2021) Biparatopic protein nanoparticles for the precision therapy of CXCR4(+) cancers. Cancers 13(12):2929PubMedPubMedCentral
Cao H, Gao Y, Wang R, Guo Q, Hui H (2020) Wogonin reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12-CXCR4/7 axis in bone marrow microenvironment. Ann Transl Med 8(17):1046PubMedPubMedCentral
Carmeliet P (2005) VEGF as a key mediator of angiogenesis in cancer. Oncology 69(Suppl. 3):4–10PubMed
Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, Parmentier M, Arenzana-Seisdedos F (1998) Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett 426(2):271–278PubMed
Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2(8):563–572PubMed
Chen Y, Zeng Z, Shi Y, Jacamo R, Ludin C, Dembowsky K, Frenette PS, Konopleva M, Andreeff M (2010) Targeting CXCR4, SDF1 and beta-adrenergic receptors in the AML microenvironment by novel antagonist POL6326, G-CSF and isoproterenol. Blood 116(21):2179
Chen XP, Qian LL, Jiang H, Chen JH (2011) Ginsenoside Rg3 inhibits CXCR4 expression and related migrations in a breast cancer cell line. Int J Clin Oncol 16(5):519–523PubMed
Chen HW, Du CW, Wei XL, Khoo US, Zhang GJ (2013) Cytoplasmic CXCR4 high-expression exhibits distinct poor clinicopathological characteristics and predicts poor prognosis in triple-negative breast cancer. Curr Mol Med 13(3):410–416PubMed
Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, Huang P, Lindeman N, Langer R, Jain RK (2019) Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci USA 116(10):4558–4566PubMedPubMedCentral
Cheng C-W, Liao W-L, Chen P-M, Yu J-C, Shiau H-P, Hsieh Y-H, Lee H-J, Cheng Y-C, Wu P-E, Shen C-Y (2021) miR-139 modulates cancer stem cell function of human breast cancer through targeting CXCR4. Cancers 13(11):2582PubMedPubMedCentral
Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD, Cher ML (2006) CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 66(1):32–48PubMed
Chittasupho C, Lirdprapamongkol K, Kewsuwan P, Sarisuta N (2014) Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles. Eur J Pharm Biopharm 88(2):529–538PubMed
Cho B-S, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, Protopopova M, Cortes J, Marszalek JR, Peng S-B (2015) Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood J Ame Soc Hematol 126(2):222–232
Choe Y, Pleasure SJ (2012) Wnt signaling regulates intermediate precursor production in the postnatal dentate gyrus by regulating CXCR4 expression. Dev Neurosci 34(6):502–514PubMed
Choi JH, Nguyen MP, Jung SY, Kwon SM, Jee JG, Bae JS, Lee S, Lee MY, Lee YM (2013) Inhibitory effect of glyceollins on vasculogenesis through suppression of endothelial progenitor cell function. Mol Nutr Food Res 57(10):1762–1771PubMed
Choueiri TK, Atkins MB, Rose TL, Alter RS, Ju Y, Niland K, Wang Y, Arbeit R, Parasuraman S, Gan L (2021) A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. Investig New Drugs 39(4):1019–1027
Chu C-Y, Cha S-T, Lin W-C, Lu P-H, Tan C-T, Chang C-C, Lin B-R, Jee S-H, Kuo M-L (2009) Stromal cell-derived factor-1α (SDF-1α/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2–NF-κB/interleukin-6 pathway. Carcinogenesis 30(2):205–213PubMed
Chung DT, Chang L-W, Huang Y-H, Tsai C-Y, Hsu C-H, King C-HR, Yuan JH, Yen C-F, Chen Y-M, Lu YC (2009) TG-0054, a novel and potent stem cell mobilizer, displays excellent PK/PD and safety profile in phase I trial. Blood 114(22):866
Cojoc M, Peitzsch C, Trautmann F, Polishchuk L, Telegeev GD, Dubrovska A (2013) Emerging targets in cancer management: role of the CXCL12/CXCR4 axis. Onco Targets Ther 6:1347–1361PubMedPubMedCentral
Dadras F, Sheikh V, Khoshjou F (2017) Epithelial and endothelial mesenchymal transition and their role in diabetic kidney disease. J Renal Inj Prev 7(1):1–6
Darwish MM, Riad AY, Salem DA, Essa AE, Shakweer MM, Sherif DEM (2021) Prognostic implication of PD-L1 expression and associated tumor infiltrating lymphocytes in metastatic breast cancer. Immunopathol Persa 8(1):e18–e18
De Clercq E (2009) The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 77(11):1655–1664PubMed
Décaillot FM, Kazmi MA, Lin Y, Ray-Saha S, Sakmar TP, Sachdev P (2011) CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J Biol Chem 286(37):32188–32197PubMedPubMedCentral
Dharwadkar A, Paul B, Buch A, Agarwal N, Naik M, Gore C (2022) Cytological study of salivary gland lesions along with histopathological correlation in a tertiary care centre. Int J Sci Res Dental Med Sci 4(3):101–109
Dubrovska A, Hartung A, Bouchez L, Walker J, Reddy V, Cho C, Schultz P (2012) CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer 107(1):43–52PubMedPubMedCentral
Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK (2011) CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res 17(8):2074–2080PubMedPubMedCentral
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174PubMed
Engl T, Relja B, Marian D, Blumenberg C, Müller I, Beecken W-D, Jones J, Ringel EM, Bereiter-Hahn J, Jonas D (2006) CXCR4 chemokine receptor mediates prostate tumor cell adhesion through α5 and β3 integrins. Neoplasia 8(4):290–301PubMedPubMedCentral
Fahham D, Weiss ID, Abraham M, Beider K, Hanna W, Shlomai Z, Eizenberg O, Zamir G, Izhar U, Shapira OM (2012) In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer. J Thorac Cardiovasc Surg 144(5):1167-1175.e1161PubMed
Fang X, Fang X, Mao Y, Ciechanover A, Xu Y, An J, Huang Z (2021) A novel small molecule CXCR4 antagonist potently mobilizes hematopoietic stem cells in mice and monkeys. Stem Cell Res Ther 12(1):17PubMedPubMedCentral
Fang X, Meng Q, Zhang H, Fang X, Huang LS, Zhang X, Schooley RT, Ciechanover A, An J, Xu Y, Huang Z (2022) A fragment integrational approach to GPCR inhibition: identification of a high affinity small molecule CXCR4 antagonist. Eur J Med Chem 231:114150PubMed
Farkas D, Kraskauskas D, Drake JI, Alhussaini AA, Kraskauskiene V, Bogaard HJ, Cool CD, Voelkel NF, Farkas L (2014) CXCR4 inhibition ameliorates severe obliterative pulmonary hypertension and accumulation of C-kit(+) cells in rats. PLoS One 9(2):e89810PubMedPubMedCentral
Feng Y, Broder CC, Kennedy PE, Berger EA (1996) HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272(5263):872–877PubMed
Festuccia C, Mancini A, Gravina GL, Colapietro A, Vetuschi A, Pompili S, Ventura L, Delle Monache S, Iorio R, Del Fattore A (2020) Dual CXCR4 and E-selectin inhibitor, GMI-1359, shows anti-bone metastatic effects and synergizes with docetaxel in prostate cancer cell intraosseous growth. Cells 9(1):32
Fouladi N, Barahman M, Amani F, Bahadoram M, Eghbali S (2019) Factors associated with delayed diagnosis of breast cancer; a study in North-West of Iran. Immunopathol Persa 6(1):e02–e02
Fu Z, Zhang P, Luo H, Huang H, Wang F (2018) CXCL12 modulates the radiosensitivity of cervical cancer by regulating CD44. Mol Med Rep 18(6):5101–5108PubMed
Furusato B, Mohamed A, Uhlen M, Rhim JS (2010) CXCR4 and cancer. Pathol Int 60(7):497–505PubMed
Gagner J-P, Sarfraz Y, Ortenzi V, Alotaibi FM, Chiriboga LA, Tayyib AT, Douglas GJ, Chevalier E, Romagnoli B, Tuffin G (2017) Multifaceted CXC chemokine receptor 4 (CXCR4) inhibition interferes with anti-vascular endothelial growth factor therapy-induced glioma dissemination. Am J Pathol 187(9):2080–2094PubMedPubMedCentral
Galsky MD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S, Stille JR, Saleh M, Thornton D (2014) A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res 20(13):3581–3588PubMed
Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, Qin S, Newman W, Groopman JE (1998) The α-chemokine, stromal cell-derived factor-1α, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem 273(36):23169–23175PubMed
Garg H, Suri P, Gupta JC, Talwar G, Dubey S (2016) Survivin: a unique target for tumor therapy. Cancer Cell Int 16(1):1–14
Ghafari M, Taheri Z, Hajivandi A, Amiri M (2015) Parathyroid carcinoma; facts and views. J Parathyr Dis 3(2):37–40
Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM, Raymond E (2014) Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res 6(4):340–352PubMedPubMedCentral
Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F (2019) Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol 94(11):1244–1253PubMed
Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS (2020) A phase Ib/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma. Clin Cancer Res 26(2):344–353PubMed
Goffart N, Lombard A, Lallemand F, Kroonen J, Nassen J, Di Valentin E, Berendsen S, Dedobbeleer M, Willems E, Robe P, Bours V, Martin D, Martinive P, Maquet P, Rogister B (2017) CXCL12 mediates glioblastoma resistance to radiotherapy in the subventricular zone. Neuro Oncol 19(1):66–77PubMed
Goldsmith ZG, Dhanasekaran DN (2007) G protein regulation of MAPK networks. Oncogene 26(22):3122–3142PubMed
Gravina GL, Mancini A, Muzi P, Ventura L, Biordi L, Ricevuto E, Pompili S, Mattei C, Di Cesare E, Jannini EA, Festuccia C (2015) CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models. Prostate 75(12):1227–1246PubMed
Gravina GL, Mancini A, Colapietro A, Vitale F, Vetuschi A, Pompili S, Rossi G, Marampon F, Richardson PJ, Patient L, Patient L, Burbidge S, Festuccia C (2017a) The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models. Tumour Biol 39(6):1010428317695528PubMed
Gravina GL, Mancini A, Marampon F, Colapietro A, Delle Monache S, Sferra R, Vitale F, Richardson PJ, Patient L, Burbidge S, Festuccia C (2017b) The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma. J Hematol Oncol 10(1):5PubMedPubMedCentral
Guo Q, Gao BL, Zhang XJ, Liu GC, Xu F, Fan QY, Zhang SJ, Yang B, Wu XH (2014) CXCL12-CXCR4 axis promotes proliferation, migration, invasion, and metastasis of ovarian cancer. Oncol Res 22(5–6):247–258PubMed
Hainsworth JD, Mace JR, Reeves JA, Crane EJ, Hamid O, Stille JR, Flynt A, Polzer J, Milner A, Roberson S (2015) Randomized phase II study of sunitinib+ CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol
Hajimiri M, Khosravikia M, Khoshneviszadeh M, Pedrood K, Hosseini SZ, Asgari MS, Pirhadi S, Attarroshan M, Mobaraki K, Hosseini S (2022) Rational design, synthesis, in vitro, and in silico studies of chlorophenylquinazolin‐4 (3H)‐one containing different aryl acetohydrazides as tyrosinase inhibitors. Chem Biodivers e202100964
Halama N, Pruefer U, Frömming A, Beyer D, Eulberg D, Jungnelius JUB, Mangasarian A (2019) Experience with CXCL12 inhibitor NOX-A12 plus pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer. J Clin Oncol
Halama N, Williams A, Prüfer U, Frömming A, Beyer D, Eulberg D, Jungnelius JU, Mangasarian A (2020) Abstract CT117: phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer. Cancer Res
Hanafi MMM, Afzan A, Yaakob H, Aziz R, Sarmidi MR, Wolfender JL, Prieto JM (2017) In vitro pro-apoptotic and anti-migratory effects of Ficus deltoidea L. plant extracts on the human prostate cancer cell lines PC3. Front Pharmacol 8:895PubMedPubMedCentral
Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M (2005) CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24(27):4462–4471PubMed
Hassan S, Buchanan M, Jahan K, Aguilar-Mahecha A, Gaboury L, Muller WJ, Alsawafi Y, Mourskaia AA, Siegel PM, Salvucci O, Basik M (2011) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer 129(1):225–232PubMed
Hatse S, Princen K, De Clercq E, Rosenkilde MM, Schwartz TW, Hernandez-Abad PE, Skerlj RT, Bridger GJ, Schols D (2005) AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor. Biochem Pharmacol 70(5):752–761PubMed
He Y, Cao X, Liu X, Li X, Xu Y, Liu J, Shi J (2015) Quercetin reverses experimental pulmonary arterial hypertension by modulating the TrkA pathway. Exp Cell Res 339(1):122–134PubMed
He X, Zhu Y, Yang L, Wang Z, Wang Z, Feng J, Wen X, Cheng L, Zhu R (2021) MgFe-LDH nanoparticles: a promising leukemia inhibitory factor replacement for self-renewal and pluripotency maintenance in cultured mouse embryonic stem cells. Adv Sci (Weinheim, Baden-Wurttemberg, Germany) 8(9):2003535. https://​doi.​org/​10.​1002/​advs.​202003535
Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, Kumar S, Kishimoto H, Miller KD, Broxmeyer HE, Nakshatri H (2003) NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 278(24):21631–21638PubMed
Herbert SP, Stainier DY (2011) Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 12(9):551–564PubMedPubMedCentral
Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA (2014) The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 123(7):1032–1039PubMedPubMedCentral
Hooshyar N, Hassanzadeh S, Nasri H (2018) Acute and chronic kidney disease in lung cancer; an update. J Renal Endocrinol 4:e22
Hsu WT, Jui HY, Huang YH, Su MY, Wu YW, Tseng WY, Hsu MC, Chiang BL, Wu KK, Lee CM (2015) CXCR4 antagonist TG-0054 mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction. Cell Transplant 24(7):1313–1328PubMed
Hu T-H, Yao Y, Yu S, Han L-L, Wang W-J, Guo H, Tian T, Ruan Z-P, Kang X-M, Wang J (2014) SDF-1/CXCR4 promotes epithelial–mesenchymal transition and progression of colorectal cancer by activation of the Wnt/β-catenin signaling pathway. Cancer Lett 354(2):417–426PubMed
Hu Y, Zang J, Qin X, Yan D, Cao H, Zhou L, Ni J, Yu S, Wu J, Feng J-F (2017) Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin. Onco Targets Ther 10:2341PubMedPubMedCentral
Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A (2009) A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231–236PubMed
Huynh C, Dingemanse J, Meyer Zu Schwabedissen HE, Sidharta PN (2020) Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions. Pharmacol Res 161:105092PubMed
Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, Tanaka R, Hirose K, Bannai K, Edamatsu T, Yanaka M, Niitani Y, Miyano-Kurosaki N, Takaku H, Koyanagi Y, Yamamoto N (2003) A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 100(7):4185–4190PubMedPubMedCentral
Iwasaki Y, Akari H, Murakami T, Kumakura S, Dewan MZ, Yanaka M, Yamamoto N (2009) Efficient inhibition of SDF-1α-mediated chemotaxis and HIV-1 infection by novel CXCR4 antagonists. Cancer Sci 100(4):778–781PubMed
Jafari M, Dadras F, Ghadimipour HR, Rabiei MAS, Khoshjou F (2017) Tempol effect on epithelial-mesenchymal transition induced by hyperglycemia. J Nephropathol 6(1):1-4PubMed
Jamali S, Kasraei E, Rezazadeh Kalashami A, BarriDizaj M (2020) Strategy for treating the gastric cancer: a systematic review and meta-analysis. Int J Sci Res Dental Med Sci 2(1):6–11
Jiang C, Ma S, Hu R, Wang X, Li M, Tian F, Jiang W, Zhu L, Bian Z (2018) Effect of CXCR4 on apoptosis in osteosarcoma cells via the PI3K/Akt/NF-kappabeta signaling pathway. Cell Physiol Biochem 46(6):2250–2260PubMed
Jiang K, Li J, Zhang J, Wang L, Zhang Q, Ge J, Guo Y, Wang B, Huang Y, Yang T (2019) SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy. Int Immunopharmacol 75:105818PubMed
Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ (2003) Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 17(7):1294–1300PubMed
Jung M, Rho J, Kim Y, Jung J, Jin Y, Ko Y-G, Lee J, Lee S, Lee J, Park M (2013) Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 32(2):209–221PubMed
Kaiser LM, Harms M, Sauter D, Rawat VP, Glitscher M, Hildt E, Tews D, Hunter Z, Münch J, Buske C (2021) Targeting of CXCR4 by the naturally occurring CXCR4 antagonist EPI-X4 in Waldenström’s macroglobulinemia. Cancers 13(4):826PubMedPubMedCentral
Kamal A, Wang Y, Steiner P, Mazzola A-M, Wetzel L, Passino M, McDermott B, Huang K, Bedian V, Greenberg N (2013) MEDI3185, a potent anti-CXCR4 antibody, inhibits tumor cell migration, signaling and tumor growth in preclinical models. Cancer Res
Kang H, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG (2005) The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. The Breast 14(5):360–367PubMed
Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, Pettit A, Levesque J, Romagnoli B, Patel K (2013) The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. Leukemia 27(12):2322–2331PubMedPubMedCentral
Kashyap MK, Amaya-Chanaga CI, Jones H, AlMahasnah EA, Choi MY, Kuhne MR, Cohen L, Sabbatini P, Kipps TJ, Cardarelli PM (2013) BMS-936564 (Anti-CXCR4 Antibody) induces specific leukemia cell mobilization and objective clinical responses in CLL patients treated under a phase I clinical trial. Blood 122(21):4190
Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ (2016) Ulocuplumab (BMS-936564/MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget 7(3):2809PubMed
Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY (2017) Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol 10(1):1–16
Kawaguchi N, Zhang TT, Nakanishi T (2019) Involvement of CXCR4 in Normal and Abnormal Development. Cells 8(2)
Khalili M, Ebrahimi M, Fazlzadeh A, Moradkhani A, Jamali S (2022) Evaluation of the survival rate and clinical outcome of Nanodrug Administration for the treatment of lung cancer: a systematic review and meta-analysis. Int J Sci Res Dental Med Sci 4(3):140–147
Khosravian M, Momenzadeh M, Koosha F, Alimohammadi N, Kianpour N (2022) Lung cancer risk and the inhibitors of angiotensin converting enzyme; an updated review on recent evidence. Immunopathol Persa. 8(1): e19
Khosravikia M, Rahbar-Kelishami A (2022) A simulation study of an applied approach to enhance drug recovery through electromembrane extraction. J Mol Liq 358:119210
Kim SY, Lee CH, Midura BV, Yeung C, Mendoza A, Hong SH, Ren L, Wong D, Korz W, Merzouk A, Salari H, Zhang H, Hwang ST, Khanna C, Helman LJ (2008) Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 25(3):201–211PubMed
Krohn A, Song YH, Muehlberg F, Droll L, Beckmann C, Alt E (2009) CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. Cancer Lett 280(1):65–71PubMed
Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf DJ, Zhang J, Ratajczak J, Ratajczak MZ (2004) CXCR4–SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 35(3):233–245PubMed
Kuhne MR, Mulvey T, Belanger B, Chen S, Pan C, Chong C, Cao F, Niekro W, Kempe T, Henning KA (2013) BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res 19(2):357–366PubMed
Kun-Ming C, Chih-Hsien C, Chen-Fang L, Ting-Jung W, Hong-Shiue C, Wei-Chen L (2020) Potential anticancer effect of celastrol on hepatocellular carcinoma by suppressing CXCR4-related signal and impeding tumor growth in vivo. Arch Med Res 51(4):297–302PubMed
Kwong J, Kulbe H, Wong D, Chakravarty P, Balkwill F (2009) An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther 8(7):1893–1905PubMed
Lafleur MA, Handsley MM, Edwards DR (2003) Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 5(23):1–39PubMed
Lefort S, Thuleau A, Kieffer Y, Sirven P, Bieche I, Marangoni E, Vincent-Salomon A, Mechta-Grigoriou F (2017) CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene 36(9):1211–1222PubMed
Li DW, Liu ZQ, Wei J, Liu Y, Hu LS (2012) Contribution of endothelial progenitor cells to neovascularization (review). Int J Mol Med 30(5):1000–1006PubMed
Li G, Badin G, Zhao A, Gentil-Perret A, Tostain J, Peoc’h M, Gigante M (2013) Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma. Histol Histopathol 28(9):1217–1222PubMed
Li SH, Dong WC, Fan L, Wang GS (2016a) Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811. Am J Transl Res 8(9):3812–3821PubMedPubMedCentral
Li X, Han Y, Zhou Q, Jie H, He Y, Han J, He J, Jiang Y, Sun E (2016b) Apigenin, a potent suppressor of dendritic cell maturation and migration, protects against collagen-induced arthritis. J Cell Mol Med 20(1):170–180PubMed
Li X, Kuang Y, Huang X, Zou L, Huang L, Yang T, Li W, Yang Y (2016c) Preparation and characterization of a new monoclonal antibody against CXCR4 using lentivirus vector. Int Immunopharmacol 36:100–105PubMed
Li J, Zhao J, Tan T, Liu M, Zeng Z, Zeng Y, Zhang L, Fu C, Chen D, Xie T (2020) Nanoparticle drug delivery system for glioma and its efficacy improvement strategies: a comprehensive review. Int J nanomedicine 15:2563–2582. https://​doi.​org/​10.​2147/​IJN.​S243223
Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H (2004) Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64(12):4302–4308PubMed
Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, Shim H (2007a) CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 359(3):716–722PubMedPubMedCentral
Liang Z, Wu H, Reddy S, Zhu A, Wang S, Blevins D, Yoon Y, Zhang Y, Shim H (2007b) Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 363(3):542–546PubMed
Liang Z, Zhan W, Zhu A, Yoon Y, Lin S, Sasaki M, Klapproth JM, Yang H, Grossniklaus HE, Xu J, Rojas M, Voll RJ, Goodman MM, Arrendale RF, Liu J, Yun CC, Snyder JP, Liotta DC, Shim H (2012) Development of a unique small molecule modulator of CXCR4. PLoS ONE 7(4):e34038PubMedPubMedCentral
Liang Z, Bian X, Shim H (2014) Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression. Breast Cancer Res Treat 146(3):535–542PubMed
Liekens S, Schols D, Hatse S (2010) CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16(35):3903–3920PubMed
Ling X, Spaeth E, Chen Y, Shi Y, Zhang W, Schober W, Hail N Jr, Konopleva M, Andreeff M (2013) The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One 8(3):e58426PubMedPubMedCentral
Liu H, Fan W (2020) MiRNA-1246 suppresses the proliferation and migration of renal cell carcinoma through targeting CXCR4. Eur Rev Med Pharmacol Sci 24(11):5979–5987PubMed
Liu CF, Liu SY, Min XY, Ji YY, Wang N, Liu D, Ma N, Li ZF, Li K (2014) The prognostic value of CXCR4 in ovarian cancer: a meta-analysis. PLoS ONE 9(3):e92629PubMedPubMedCentral
Liu P, Long P, Huang Y, Sun F, Wang Z (2016) CXCL12/CXCR4 axis induces proliferation and invasion in human endometrial cancer. Am J Transl Res 8(4):1719–1729PubMedPubMedCentral
Liu SH, Gu Y, Pascual B, Yan Z, Hallin M, Zhang C, Fan C, Wang W, Lam J, Spilker ME, Yafawi R, Blasi E, Simmons B, Huser N, Ho WH, Lindquist K, Tran TT, Kudaravalli J, Ma JT, Jimenez G, Barman I, Brown C, Chin SM, Costa MJ, Shelton D, Smeal T, Fantin VR, Pernasetti F (2017) A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies. Blood Adv 1(15):1088–1100PubMedPubMedCentral
Ludwig H, Weisel K, Petrucci M, Leleu X, Cafro A, Garderet L, Leitgeb C, Foa R, Greil R, Yakoub-Agha I (2017) Olaptesed pegol, an anti-CXCL12/SDF-1 spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a phase IIa study. Leukemia 31(4):997–1000PubMedPubMedCentral
Luker GD, Yang J, Richmond A, Scala S, Festuccia C, Schottelius M, Wester HJ, Zimmermann J (2021) At the bench: pre-clinical evidence for multiple functions of CXCR4 in cancer. J Leukoc Biol 109(5):969–989PubMed
Luo HN, Wang ZH, Sheng Y, Zhang Q, Yan J, Hou J, Zhu K, Cheng Y, Xu YL, Zhang XH, Xu M, Ren XY (2014) MiR-139 targets CXCR4 and inhibits the proliferation and metastasis of laryngeal squamous carcinoma cells. Med Oncol 31(1):789PubMed
Luttrell LM, Gesty-Palmer D (2010) Beyond desensitization: physiological relevance of arrestin-dependent signaling. Pharmacol Rev 62(2):305–330PubMedPubMedCentral
Mansoori B, Mohammadi A, Hashemzadeh S, Shirjang S, Baradaran A, Asadi M, Doustvandi MA, Baradaran B (2017) Urtica dioica extract suppresses miR-21 and metastasis-related genes in breast cancer. Biomed Pharmacother 93:95–102PubMed
Manu KA, Shanmugam MK, Rajendran P, Li F, Ramachandran L, Hay HS, Kannaiyan R, Swamy SN, Vali S, Kapoor S, Ramesh B, Bist P, Koay ES, Lim LH, Ahn KS, Kumar AP, Sethi G (2011) Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer 10(1):107PubMedPubMedCentral
Marchese A, Raiborg C, Santini F, Keen JH, Stenmark H, Benovic JL (2003) The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Dev Cell 5(5):709–722PubMed
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773(8):1263–1284PubMed
Mellado M, Rodriguez-Frade JM, Manes S, Martinez AC (2001) Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol 19(1):397–421PubMed
Mirshahi F, Pourtau J, Li H, Muraine M, Trochon V, Legrand E, Vannier J, Soria J, Vasse M, Soria C (2000) SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. Thromb Res 99(6):587–594PubMed
Mori T, Doi R, Koizumi M, Toyoda E, Ito D, Kami K, Masui T, Fujimoto K, Tamamura H, Hiramatsu K, Fujii N, Imamura M (2004) CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer. Mol Cancer Ther 3(1):29–37PubMed
Mosaddad SA, Salari Y, Amookhteh S, Soufdoost RS, Seifalian A, Bonakdar S et al (2021) Response to mechanical cues by interplay of YAP/TAZ transcription factors and key mechanical checkpoints of the cell: a comprehensive review. Cell Physiol Biochem 55(1):33–60
Mosaddad SA, Rasoolzade B, Namanloo RA, Azarpira N, Dortaj H (2022) Stem cells and common biomaterials in dentistry: a review study. J Mater Sci: Mater Med 33(7):55PubMed
Mosi RM, Anastassova V, Cox J, Darkes MC, Idzan SR, Labrecque J, Lau G, Nelson KL, Patel K, Santucci Z, Wong RS, Skerlj RT, Bridger GJ, Huskens D, Schols D, Fricker SP (2012) The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor. Biochem Pharmacol 83(4):472–479PubMed
Mosley CA, Wilson LJ, Wiseman JM, Skudlarek JW, Liotta DC (2009) Recent patents regarding the discovery of small molecule CXCR4 antagonists. Expert Opin Ther Pat 19(1):23–38PubMed
Mousavi A (2020) CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy. Immunol Lett 217:91–115PubMed
Moyle G, DeJesus E, Boffito M, Wong RS, Gibney C, Badel K, MacFarland R, Calandra G, Bridger G, Becker S, X. A. C. T. S. Team (2009) Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis 48(6):798–805PubMed
Mukherjee D, Zhao J (2013) The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 3(1):46–57PubMedPubMedCentral
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56PubMed
Murakami T, Zhang TY, Koyanagi Y, Tanaka Y, Kim J, Suzuki Y, Minoguchi S, Tamamura H, Waki M, Matsumoto A, Fujii N, Shida H, Hoxie JA, Peiper SC, Yamamoto N (1999) Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 73(9):7489–7496PubMedPubMedCentral
Murakami T, Maki W, Cardones AR, Fang H, Tun Kyi A, Nestle FO, Hwang ST (2002) Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 62(24):7328–7334PubMed
Murakami T, Cardones AR, Hwang ST (2004) Chemokine receptors and melanoma metastasis. J Dermatol Sci 36(2):71–78PubMed
Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y, Kanda K, Kawada M, Seno H, Taketo MM, Sakai Y (2013) The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer 132(2):276–287PubMed
Murdoch C (2000) CXCR4: chemokine receptor extraordinaire. Immunol Rev 177:175–184PubMed
Murphy PM (2001) Chemokines and the molecular basis of cancer metastasis. N Engl J Med 345(11):833–835PubMed
Muz B, Azab F, Fiala M, King J, Kohnen D, Fogler WE, Smith T, Magnani JL, Vij R, Azab AK (2019) Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy. Blood Cancer J 9(9):68PubMedPubMedCentral
Nagasawa T (2014) CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4. J Mol Med (berl) 92(5):433–439PubMed
Nagasawa T, Kikutani H, Kishimoto T (1994) Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A 91(6):2305–2309PubMedPubMedCentral
Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T (1996) Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382(6592):635–638PubMed
Nakamura T, Shinriki S, Jono H, Guo J, Ueda M, Hayashi M, Yamashita S, Zijlstra A, Nakayama H, Hiraki A (2015) Intrinsic TGF-β2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells. Oncotarget 6(2):1008PubMed
Nengroo MA, Maheshwari S, Singh A, Verma A, Arya RK, Chaturvedi P, Saini KK, Singh AK, Sinha A, Meena S, Gupta A, Mishra A, Sarkar J, Datta D (2021) CXCR4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5. Cell Death Dis 12(5):464PubMedPubMedCentral
Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF (2009) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113(24):6206–6214PubMedPubMedCentral
O’Boyle G, Swidenbank I, Marshall H, Barker C, Armstrong J, White S, Fricker S, Plummer R, Wright M, Lovat P (2013) Inhibition of CXCR4–CXCL12 chemotaxis in melanoma by AMD11070. Br J Cancer 108(8):1634–1640PubMedPubMedCentral
Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell Commun Signal 121(3):335–348
Ottaiano A, di Palma A, Napolitano M, Pisano C, Pignata S, Tatangelo F, Botti G, Acquaviva AM, Castello G, Ascierto PA, Iaffaioli RV, Scala S (2005) Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol Immunother 54(8):781–791PubMed
Pattarozzi A, Gatti M, Barbieri F, Würth R, Porcile C, Lunardi G, Ratto A, Favoni R, Bajetto A, Ferrari A (2008) 17β-Estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment. Mol Pharmacol 73(1):191–202PubMed
Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, Tiomkin L, Ribakovsky L, Riback Y, Ramati Y (2014) The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res 20(2):469–479PubMed
Peng L, Damschroder MM, Cook KE, Wu H, Dall’Acqua WF (2016a) Molecular basis for the antagonistic activity of an anti-CXCR4 antibody. Mabs 8:163–175PubMed
Peng SB, Zhang X, Paul D, Kays LM, Ye M, Vaillancourt P, Dowless M, Stancato LF, Stewart J, Uhlik MT, Long H, Chu S, Obungu VH (2016b) Inhibition of CXCR4 by LY2624587, a fully humanized anti-CXCR4 antibody induces apoptosis of hematologic malignancies. PLoS One 11(3):e0150585PubMedPubMedCentral
Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J (2018) Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol 19(6):812–824PubMed
Petit I, Jin D, Rafii S (2007) The SDF-1–CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28(7):299–307PubMedPubMedCentral
Porvasnik S, Sakamoto N, Kusmartsev S, Eruslanov E, Kim WJ, Cao W, Urbanek C, Wong D, Goodison S, Rosser CJ (2009) Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 69(13):1460–1469PubMed
Pozzobon T, Goldoni G, Viola A, Molon B (2016) CXCR4 signaling in health and disease. Immunol Lett 177:6–15PubMed
Ranjbarnejad T, Saidijam M, Moradkhani S, Najafi R (2017) Methanolic extract of Boswellia serrata exhibits anti-cancer activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells. Prostaglandins Other Lipid Mediat 131:1–8PubMed
Rasti A, Abolhasani M, Zanjani LS, Asgari M, Mehrazma M, Madjd Z (2017) Reduced expression of CXCR4, a novel renal cancer stem cell marker, is associated with high-grade renal cell carcinoma. J Cancer Res Clin Oncol 143(1):95–104PubMed
Ratajczak M, Zuba-Surma E, Kucia M, Reca R, Wojakowski W, Ratajczak J (2006) The pleiotropic effects of the SDF-1–CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20(11):1915–1924PubMed
Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR (2009) Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 21(3):761–767PubMed
Rubin JB (2009) Chemokine signaling in cancer: one hump or two? Semin Cancer Biol 19(2):116–122PubMed
Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A, Spigel DR (2017a) A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer 105:7–13PubMed
Salgia R, Stille JR, Weaver RW, McCleod M, Hamid O, Polzer J, Roberson S, Flynt A, Spigel DRJLC (2017b) A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive-disease small cell lung cancer. Lung Cancer 105:7–13PubMed
Samara GJ, Lawrence DM, Chiarelli CJ, Valentino MD, Lyubsky S, Zucker S, Vaday GG (2004) CXCR4-mediated adhesion and MMP-9 secretion in head and neck squamous cell carcinoma. Cancer Lett 214(2):231–241PubMed
Sánchez-Martín L, Estecha A, Samaniego R, Sánchez-Ramón S, Vega MÁ, Sánchez-Mateos P (2011) The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood, the Journal of the American Society of Hematology 117(1):88–97
Scala S (2015) Molecular pathways: targeting the CXCR4–CXCL12 axis—untapped potential in the tumor microenvironment. Clin Cancer Res 21(19):4278–4285PubMed
Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11(5):1835–1841PubMed
Scala S, Giuliano P, Ascierto PA, Ierano C, Franco R, Napolitano M, Ottaiano A, Lombardi ML, Luongo M, Simeone E, Castiglia D, Mauro F, De Michele I, Calemma R, Botti G, Caraco C, Nicoletti G, Satriano RA, Castello G (2006) Human melanoma metastases express functional CXCR4. Clin Cancer Res 12(8):2427–2433PubMed
Schottelius M, Herrmann K, Lapa C (2021) In vivo targeting of CXCR4-new horizons. Cancers (basel) 13(23):5920PubMed
Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR (2002) Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 62(20):5930–5938PubMed
Seif F, Kheirollah A, Babaahmadi-Rezaei H (2020) Efficient isolation and identification of primary endothelial cells from bovine aorta by collagenase P. Immunopathol Persa 6(2):e15
Setia G, Hagog N, Jalilizeinali B, Funkhouser S, Pierzchanowski L, Lan F, Gabig TG, Kiner-Strachan B, Kelleher K, Hsu M-C (2015) A phase II, open-label pilot study to evaluate the hematopoietic stem cell mobilization of TG-0054 combined with G-CSF in 12 patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin lymphoma-an interim analysis. Blood
Shahverdi M, Hajiasgharzadeh K, Sorkhabi AD, Jafarlou M, Shojaee M, Tabrizi NJ, Alizadeh N, Santarpia M, Brunetti O, Safarpour H (2022) The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. Biomed Pharmacother 148:112735PubMed
Shanmugam MK, Ahn KS, Lee JH, Kannaiyan R, Mustafa N, Manu KA, Siveen KS, Sethi G, Chng WJ, Kumar AP (2018) Celastrol attenuates the invasion and migration and augments the anticancer effects of bortezomib in a xenograft mouse model of multiple myeloma. Front Pharmacol 9:365PubMedPubMedCentral
Shariati Y, Salehi Kahrizsangi F, Hozhabrossadati N, Naseri D, Ebrahimi M (2022) Evaluate the clinical outcome of nanoparticle albumin-bound paclitaxel on breast cancer treatment: a systematic review and meta-analysis. Int J Sci Res Dental Med Sci 4(3):127–133
Shi Y, Riese DJ 2nd, Shen J (2020) The role of the CXCL12/CXCR4/CXCR7 chemokine axis in cancer. Front Pharmacol 11:574667PubMedPubMedCentral
Shomali N, Baradaran B, Sorkhabi AD, Sarkesh A, Kahrizi MS, Tosan F, Mahmoodpoor A, Mardi A, Mohammadi H, Hassanzadeh A (2022a) Survivin; a novel therapeutic target that correlates with survival of autoreactive T lymphocytes obtained from patients with ankylosing spondylitis. Gene 844:146829PubMed
Shomali N, Suliman Maashi M, Baradaran B, Daei Sorkhabi A, Sarkesh A, Mohammadi H, Hemmatzadeh M, Marofi F, Sandoghchian Shotorbani S, M. Jarahian (2022b) Dysregulation of survivin-targeting microRNAs in autoimmune diseases: new perspectives for novel therapies. Front Immunol 848
Si H, Wang H, Xiao H, Fang Y, Wu Z (2021) Anti-tumor effect of celastrol on hepatocellular carcinoma by the circ_SLIT3/miR-223-3p/CXCR4 Axis. Cancer Manag Res 13:1099–1111PubMedPubMedCentral
Singh S, Srivastava SK, Bhardwaj A, Owen LB, Singh AP (2010) CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 103(11):1671–1679PubMedPubMedCentral
Sison EAR, Magoon D, Li L, Annesley CE, Romagnoli B, Douglas GJ, Tuffin G, Zimmermann J, Brown P (2015) POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. Oncotarget 6(31):30902PubMedPubMedCentral
Sonbol H, Ameen F, AlYahya S, Almansob A, Alwakeel S (2021) Padina boryana mediated green synthesis of crystalline palladium nanoparticles as potential nanodrug against multidrug resistant bacteria and cancer cells. Sci Rep 11(1):1–9
Song JS, Chang CC, Wu CH, Dinh TK, Jan JJ, Huang KW, Chou MC, Shiue TY, Yeh KC, Ke YY, Yeh TK, Ta YN, Lee CJ, Huang JK, Sung YC, Shia KS, Chen Y (2021) A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment. Proc Natl Acad Sci USA 118(13):e2015433118PubMedPubMedCentral
Sorkhabi AD, Sarkesh A, Fotouhi A, Saeedi H,. Aghebati-Maleki L (2022a) "Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma. IUBMB life
Sorkhabi AD, Sarkesh A, Saeedi H, Marofi F, Ghaebi M, Silvestris N, B Baradaran N, Brunetti O (2022b) The basis and advances in clinical application of cytomegalovirus-specific cytotoxic T cell immunotherapy for glioblastoma multiforme. Front Oncol 12
Spinello I, Quaranta MT, Riccioni R, Riti V, Pasquini L, Boe A, Pelosi E, Vitale A, Foa R, Testa U, Labbaye C (2011) MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias. Blood Cancer J 1(6):e26PubMedPubMedCentral
Steurer M, Montillo M, Scarfo L, Mauro FR, Andel J, Wildner S, Trentin L, Janssens A, Burgstaller S, Fromming A, Dummler T, Riecke K, Baumann M, Beyer D, Vauleon S, Ghia P, Foa R, Caligaris-Cappio F, Gobbi M (2019) Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica 104(10):2053–2060PubMedPubMedCentral
Stone ND, Dunaway SB, Flexner C, Tierney C, Calandra GB, Becker S, Cao YJ, Wiggins IP, Conley J, MacFarland RT, Park JG, Lalama C, Snyder S, Kallungal B, Klingman KL, Hendrix CW (2007) Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 51(7):2351–2358PubMedPubMedCentral
Strizki JM, Turner JD, Collman RG, Hoxie J, González-Scarano F (1997) A monoclonal antibody (12G5) directed against CXCR-4 inhibits infection with the dual-tropic human immunodeficiency virus type 1 isolate HIV-1 (89.6) but not the T-tropic isolate HIV-1 (HxB). J Virol 71(7):5678–5683PubMedPubMedCentral
Sugiyama T, Kohara H, Noda M, Nagasawa T (2006) Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 25(6):977–988PubMed
Sun Y, Cheng Z, Ma L, Pei G (2002) β-Arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem 277(51):49212–49219PubMed
Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J (2010) CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29(4):709–722PubMedPubMedCentral
Sung B, Jhurani S, Ahn KS, Mastuo Y, Yi T, Guha S, Liu M, Aggarwal BB (2008) Zerumbone down-regulates chemokine receptor CXCR4 expression leading to inhibition of CXCL12-induced invasion of breast and pancreatic tumor cells. Cancer Res 68(21):8938–8944PubMed
Suzuki Y, Rahman M, Mitsuya H (2001) Diverse transcriptional response of CD4+ T cells to stromal cell-derived factor SDF-1: cell survival promotion and priming effects of SDF-1 on CD4+ T cells. J Immunol 167(6):3064–3073PubMed
Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S-I (1998) The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 393(6685):591–594PubMed
Tahirovic YA, Pelly S, Jecs E, Miller EJ, Sharma SK, Liotta DC, Wilson LJ (2020) Small molecule and peptide-based CXCR4 modulators as therapeutic agents. A patent review for the period from 2010 to 2018. Expert Opin Ther Pat 30(2):87–101PubMed
Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, Omagari A, Otaka A, Ibuka T, Yamamoto N, Nakashima H, Fujii N (1998) A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun 253(3):877–882PubMed
Tamamura H, Omagari A, Hiramatsu K, Gotoh K, Kanamoto T, Xu Y, Kodama E, Matsuoka M, Hattori T, Yamamoto N (2001) Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett 11(14):1897–1902PubMed
Tamamura H, Tsutsumi H, Fujii N (2006) The chemokine receptor CXCR4 as a therapeutic target for several diseases. Mini Rev Med Chem 6(9):989–995PubMed
Tavor S, Weiss I, Beider K, Wald H, Eizenberg O, Pereg Y, Klapper L, Nagler A, Peled A, Abraham M (2013) The CXCR4 antagonist BL-8040 efficiently induces apoptosis and inhibits the survival of AML cells. Blood 122(21):3939
Teicher BA, Fricker SP (2010) CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16(11):2927–2931PubMed
Teixido J, Martinez-Moreno M, Diaz-Martinez M, Sevilla-Movilla S (2018) The good and bad faces of the CXCR4 chemokine receptor. Int J Biochem Cell Biol 95:121–131PubMed
Thomas RP, Nagpal S, Iv M, Soltys SG, Corbin Z, Xu LW, Recht CK, Bertrand S, Jain V, Acevedo B (2016) A phase I study of chemo-radiotherapy with plerixafor for newly diagnosed glioblastoma (GB). J Clin Oncol
Ullah TR (2019) The role of CXCR4 in multiple myeloma: Cells’ journey from bone marrow to beyond. J Bone Oncol 17:100253PubMedPubMedCentral
Uy GL, Avigan D, Cortes JE, Becker PS, Chen RW, Liesveld JL, Hewes B, Johns D, Erba HP (2011) Safety and tolerability of plerixafor in combination with cytarabine and daunorubicin in patients with newly diagnosed acute myeloid leukemia-preliminary results from a phase I study. Blood 118(21):82
Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM, Kulkarni S, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Vij R, Westervelt P, DiPersio JF (2012) A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 119(17):3917–3924PubMedPubMedCentral
Van Hout A, D’Huys T, Oeyen M, Schols D, Van Loy T (2017) Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors. PLoS One 12(4):e0176057PubMedPubMedCentral
Vandercappellen J, Van Damme J, Struyf S (2008) The role of CXC chemokines and their receptors in cancer. Cancer Lett 267(2):226–244PubMed
Vazirabad AF, Noorolyai S, Baghbani E, Mahboob S, Zargari F, Rahmani S, Sorkhabi A, Montazami N, Sameti P, Baradaran B (2022) Silencing of SiX-4 enhances the chemosensitivity of melanoma cells to Cisplatin. Pathol Res Pract 240:154194PubMed
Vila-Coro AJ, Rodríguez-Frade JM, De Ana AM, Moreno-Ortíz MC, Martínez-A C, Mellado M (1999) The chemokine SDF-lα triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 13(13):1699–1710PubMed
Vitale RM, Gatti M, Carbone M, Barbieri F, Felicità V, Gavagnin M, Florio T, Amodeo P (2013) Minimalist hybrid ligand/receptor-based pharmacophore model for CXCR4 applied to a small-library of marine natural products led to the identification of phidianidine a as a new CXCR4 ligand exhibiting antagonist activity. ACS Chem Biol 8(12):2762–2770PubMed
Wang J-F, Park I-W, Groopman JE (2000) Stromal cell-derived factor-1α stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C. J Am Soc Hematol 95(8):2505–2513
Wang Z, Ma Q, Liu Q, Yu H, Zhao L, Shen S, Yao J (2008) Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer 99(10):1695–1703PubMedPubMedCentral
Wang L, Wang L, Yang B, Yang Q, Qiao S, Wang Y, Sun Y (2009) Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clin Exp Metastasis 26(8):1049–1054PubMed
Wang Y, Chen Y, Wang J, Chen J, Aggarwal B, Pang X, Liu M (2012) Xanthohumol, a prenylated chalcone derived from hops, suppresses cancer cell invasion through inhibiting the expression of CXCR4 chemokine receptor. Curr Mol Med 12(2):153–162PubMed
Wang L, Li W, Lin M, Garcia M, Mulholland D, Lilly M, Martins-Green M (2014a) Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis 35(10):2321–2330PubMedPubMedCentral
Wang Y, Liang WC, Pan WL, Law WK, Hu JS, Ip DT, Waye MM, Ng TB, Wan DC (2014b) Silibinin, a novel chemokine receptor type 4 antagonist, inhibits chemokine ligand 12-induced migration in breast cancer cells. Phytomedicine 21(11):1310–1317PubMed
Wang Y, Miao H, Li W, Yao J, Sun Y, Li Z, Zhao L, Guo Q (2014c) CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells. Biochem Pharmacol 90(3):212–225PubMed
Wang X, Li F, Zhou X (2016) miR-204-5p regulates cell proliferation and metastasis through inhibiting CXCR4 expression in OSCC. Biomed Pharmacother 82:202–207PubMed
Wang S, Chen C, Li J, Xu X, Chen W, Li F (2020) The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1. J Neurol Sci 414:116837PubMed
Werner TA, Forster CM, Dizdar L, Verde PE, Raba K, Schott M, Knoefel WT, Krieg A (2018) CXCR4/CXCR7/CXCL12-axis in follicular thyroid carcinoma. J Cancer 9(6):929–940PubMedPubMedCentral
Wong D, Korz W (2008) Translating an antagonist of chemokine receptor CXCR4: from bench to bedside. Clin Cancer Res 14(24):7975–7980PubMed
Wu PF, Lu ZP, Cai BB, Tian L, Zou C, Jiang KR, Miao Y (2013) Role of CXCL12/CXCR4 signaling axis in pancreatic cancer. Chin Med J (engl) 126(17):3371–3374PubMed
Wu Y, Tang S-J, Sun G, Sun K (2016) CXCR7 mediates TGFβ1-promoted EMT and tumor-initiating features in lung cancer. Oncogene 35(16):2123–2132PubMed
Wu X, Zhang H, Sui Z, Gao Y, Gong L, Chen C, Ma Z, Tang P, Yu Z (2022) CXCR4 promotes the growth and metastasis of esophageal squamous cell carcinoma as a critical downstream mediator of HIF-1α. Cancer Sci 113:926PubMedPubMedCentral
Würth R, Bajetto A, Harrison JK, Barbieri F, Florio T (2014) CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci 8:144PubMedPubMedCentral
Xia R, Xu G, Huang Y, Sheng X, Xu X, Lu H (2018) Hesperidin suppresses the migration and invasion of non-small cell lung cancer cells by inhibiting the SDF-1/CXCR-4 pathway. Life Sci 201:111–120PubMed
Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL, Dembowsky K, Weilbaecher KN (2015) CXCR4 protein epitope mimetic antagonist POL5551 disrupts metastasis and enhances chemotherapy effect in triple-negative breast cancer. Mol Cancer Ther 14(11):2473–2485PubMedPubMedCentral
Xu L, Li C, Hua F, Liu X (2021) The CXCL12/CXCR7 signalling axis promotes proliferation and metastasis in cervical cancer. Med Oncol 38(5):58PubMed
Xue Y, Xu W, Zhao W, Wang W, Zhang D, Wu P (2017) miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4. Biomed Pharmacother 86:426–433PubMed
Yadav VR, Sung B, Prasad S, Kannappan R, Cho S-G, Liu M, Chaturvedi MM, Aggarwal BB (2010) Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor. J Mol Med 88(12):1243–1253PubMed
Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D, Rubin JB (2007) Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 67(2):651–658PubMed
Yang P, Wang G, Huo H, Li Q, Zhao Y, Liu Y (2015) SDF-1/CXCR4 signaling up-regulates survivin to regulate human sacral chondrosarcoma cell cycle and epithelial–mesenchymal transition via ERK and PI3K/AKT pathway. Med Oncol 32(1):1–7
Yazdani A, Namdari F, Gorgani-Firuzjaee S, Niroomand H (2022) Evaluation of the urine mRNA-PCA3 expression level in prostate patients; comparison between benign prostatic hyperplasia and cancer. Immunopathol Persa 8(2): e15207
Ye C, Zhang C, Huang H, Yang B, Xiao G, Kong D, Tian Q, Song Q, Song Y, Tan H, Wang Y, Zhou T, Zi X, Sun Y (2018) The natural compound myricetin effectively represses the malignant progression of prostate cancer by inhibiting PIM1 and disrupting the PIM1/CXCR4 interaction. Cell Physiol Biochem 48(3):1230–1244PubMed
Yin P, Peng R, Peng H, Yao L, Sun Y, Wen L, Wu T, Zhou J, Zhang Z (2015) MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells. Mol Biotechnol 57(1):1–11PubMed
Yin X, Liu Z, Zhu P, Wang Y, Ren Q, Chen H, Xu J (2019) CXCL12/CXCR4 promotes proliferation, migration, and invasion of adamantinomatous craniopharyngiomas via PI3K/AKT signal pathway. J Cell Biochem 120(6):9724–9736PubMed
Yin Z, Zhang J, Chen L, Guo Q, Yang B, Zhang W, Kang W (2020) Anticancer effects and mechanisms of action of plumbagin: review of research advances. Biomed Res Int 2020:6940953PubMedPubMedCentral
Yoon Y, Liang Z, Zhang X, Choe M, Zhu A, Cho HT, Shin DM, Goodman MM, Shim H (2007) CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Can Res 67(15):7518–7524
Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L (2011) CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res 9(2):161–172PubMed
Yuan W, Guo Y-Q, Li X-Y, Deng M-Z, Shen Z-H, Bo C-B, Dai Y-F, Huang M-Y, Yang Z-Y, Quan Y-S (2016) MicroRNA-126 inhibits colon cancer cell proliferation and invasion by targeting the chemokine (CXC motif) receptor 4 and Ras homolog gene family, member A, signaling pathway. Oncotarget 7(37):60230PubMedPubMedCentral
Zagzag D, Lukyanov Y, Lan L, Ali MA, Esencay M, Mendez O, Yee H, Voura EB, Newcomb EW (2006) Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest 86(12):1221–1232PubMed
Zainal NS, Gan CP, Lau BF, Yee PS, Tiong KH, Abdul Rahman ZA, Patel V, Cheong SC (2018) Zerumbone targets the CXCR4-RhoA and PI3K-mTOR signaling axis to reduce motility and proliferation of oral cancer cells. Phytomedicine 39:33–41PubMed
Zeelenberg IS, Ruuls-Van Stalle L, Roos E (2003) The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Can Res 63(13):3833–3839
Zeng Z, Samudio IJ, Munsell M, An J, Huang Z, Estey E, Andreeff M, Konopleva M (2006) Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 5(12):3113–3121PubMed
Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M (2009) Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113(24):6215–6224PubMedPubMedCentral
Zhan W, Liang Z, Zhu A, Kurtkaya S, Shim H, Snyder JP, Liotta DC (2007) Discovery of small molecule CXCR4 antagonists. J Med Chem 50(23):5655–5664PubMed
Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B (2015) CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget 6(7):5022–5040PubMed
Zheng N, Liu W, Chen J, Li B, Liu J, Wang J, Gao Y, Shao J, Jia L (2019) CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer. Mol Carcinog 58(1):144–155PubMed
Zhong C, Wang J, Li B, Xiang H, Ultsch M, Coons M, Wong T, Chiang NY, Clark S, Clark R, Quintana L, Gribling P, Suto E, Barck K, Corpuz R, Yao J, Takkar R, Lee WP, Damico-Beyer LA, Carano RD, Adams C, Kelley RF, Wang W, Ferrara N (2013) Development and preclinical characterization of a humanized antibody targeting CXCL12. Clin Cancer Res 19(16):4433–4445PubMed
Zhong J, Li J, Wei J, Huang D, Huo L, Zhao C, Lin Y, Chen W, Wei Y (2019) Plumbagin restrains hepatocellular carcinoma angiogenesis by stromal cell-derived factor (SDF-1)/CXCR4-CXCR7 axis. Med Sci Monit Int Med J Exp Clin Res 25:6110
Zhou W, Guo S, Liu M, Burow ME, Wang G (2019) Targeting CXCL12/CXCR4 Axis in tumor immunotherapy. Curr Med Chem 26(17):3026–3041PubMedPubMedCentral
Ziegler ME, Hatch MM, Wu N, Muawad SA, Hughes CC (2016) mTORC2 mediates CXCL12-induced angiogenesis. Angiogenesis 19(3):359–371PubMedPubMedCentral
Zielinska KA, Katanaev VL (2020) The signaling Duo CXCL12 and CXCR4: chemokine fuel for breast cancer tumorigenesis. Cancers 12(10):3071PubMedPubMedCentral
Zirafi O, Kim KA, Standker L, Mohr KB, Sauter D, Heigele A, Kluge SF, Wiercinska E, Chudziak D, Richter R, Moepps B, Gierschik P, Vas V, Geiger H, Lamla M, Weil T, Burster T, Zgraja A, Daubeuf F, Frossard N, Hachet-Haas M, Heunisch F, Reichetzeder C, Galzi JL, Perez-Castells J, Canales-Mayordomo A, Jimenez-Barbero J, Gimenez-Gallego G, Schneider M, Shorter J, Telenti A, Hocher B, Forssmann WG, Bonig H, Kirchhoff F, Munch J (2015) Discovery and characterization of an endogenous CXCR4 antagonist. Cell Rep 11(5):737–747PubMed
Zlotnik A (2008) New insights on the role of CXCR4 in cancer metastasis. J Pathol 215(3):211–213PubMed
Metadata
Title
CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment
Authors
Shunshun Bao
Mohammad Darvishi
Ali H Amin
Maysoon T. Al-Haideri
Indrajit Patra
Khadisha Kashikova
Irfan Ahmad
Fahad Alsaikhan
Zahraa Haleem Al-qaim
Moaed E. Al-Gazally
Bahman Abedi Kiasari
Bahareh Tavakoli-Far
Akmal A. Sidikov
Yasser Fakri Mustafa
Reza Akhavan-Sigari
Publication date
11-03-2023
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 10/2023
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-022-04444-w

Other articles of this Issue 10/2023

Journal of Cancer Research and Clinical Oncology 10/2023 Go to the issue

Research

The evaluation of tumor microenvironment infiltration and the identification of angiogenesis-related subgroups in skin cutaneous melanoma

Review

Cancer immune escape: the role of antigen presentation machinery

Research

Development of 177Lu-Cetuximab-PAMAM dendrimeric nanosystem: a novel theranostic radioimmunoconjugate

Research

Analyses of sex-based clinicopathological differences among patients with gastrointestinal neuroendocrine neoplasms in Europe

Research

A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival

Research

Discovery of potential biomarkers for lung cancer classification based on human proteome microarrays using Stochastic Gradient Boosting approach
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits